Search

Your search keyword '"Kristen Harrington-Smith"' showing total 2 results
Start Over Author "Kristen Harrington-Smith"
2 results on '"Kristen Harrington-Smith"'

1. List of Contributors

Author

Julie G. Allickson, Rafael G. Amado, Usman Azam, Frank Barry, Irene Aldecoa Bilbao, Gwendolyn K. Binder, Justin L. Black, Karin Blumer, Eugene P. Brandon, David A. Brindley, William Murray Burns, Francesca Capone, Guillaume Carmona, Michael Chaffman, William Chou, Zhanfeng Cui, Kevin A. D’Amour, Nathan J. Dowden, Bernd Eschgfaeller, Eric Faulkner, Maria Cristina Galli, Yoshio Goshima, Stephen J. Haggarty, Celine-Lea Halioua-Haubold, Kristen Harrington-Smith, Darren Hickerson, William Ho, Johan Hyllner, Natasha Iyer, Marieke Jansen, Etienne Jousseaume, Sven Kili, Antoinette F. Konski, Lawrence S. Lamb, Ching Lam, Jaeseung Lim, Chi Lo, Thomas Malcolm, Almudena Martinez-Fernandez, Todd Meinecke, Edward Meinert, Michael C. Milone, David A. Mitchell, Niraj Muni, Filomena Nappi, Neal H. Nathan, Emanuele Ostuni, Marianthi Papakosta, Simona Paratore, Vincenzo Lorenzo Pascali, Cameron D. Pernia, Benjamin Philipson, Fiona Phillips, James B. Phillips, Nasib Qureshi, Pietro Refolo, Moira Ringo, Matthew Robson, Crystal Ruff, Manuel Schmidt, Matthias Schroff, Michael J. Scott, Michaela Sharpe, Richard L. Sidman, John D. Sinden, Devyn M. Smith, Evan Y. Snyder, Sita Somara, Antonio Gioacchino Spagnolo, Daryl S. Spinner, Kanaka Sridharan, Michael Sullivan, Keith Thompson, Brian T.D. Tobe, Alain A. Vertès, Michael D. West, Cynthia Wilkins-Port, Burghardt Wittig, Aidong Yang, Jie Zhang, and Mark C. Zimmerman

Published
2020

2. Commercialising CAR-T Therapies

Author

Fiona Phillips, Etienne Jousseaume, Kristen Harrington-Smith, Emanuele Ostuni, Karin Blumer, Simona Paratore, Bernd Eschgfaeller, Marieke Jansen, Irene Aldecoa Bilbao, Jie Zhang, Matthew Robson, and William Chou

Subjects
medicine.medical_specialty, business.industry, Novelty, Terminally ill, Business model, Chimeric antigen receptor, Family medicine, medicine, media_common.cataloged_instance, Business, Product (category theory), Car t cells, European union, Pharmaceutical industry, media_common
Abstract

In August 2017, the FDA approved the first–ever chimeric antigen receptor T cell (CAR–T) therapy for the use in terminally ill paediatric leukaemia patients. Today, this therapy, which genetically modifies a patient’s own immune cells to enable them to effectively detect and destroy cancer cells, is approved for use in rare subsets of paediatric leukaemia and adult lymphoma in the United States, the European Union, Switzerland, Japan, Canada and Australia. CAR–T therapy is unlike any traditional pharmaceutical product and requires innovation at every single step, from R&D to global patient access. This chapter gives an overview on the key inventive actions taken by the Novartis team in the past 24 months in bringing this product to market. A special focus is given to the novelty of a business model in which the pharmaceutical industry is no longer only a provider of medicines but acts as a treatment partner. Additionally, an in–depth perspective is provided on the value discussion of such one–time therapies with prolonged medical and clinical value and the different payment models pioneered in collaboration with healthcare systems and payers.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results